

## Research Profile: Dr. med. Verena I. Gaidzik

### 1. General Information

Name, Academic Title: Dr. med. Verena Ingeborg Gaidzik  
Date and Place of Birth: 08.06.1979; Ulm, Germany  
Sex: Female  
Office Address: Department of Internal Medicine III, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany  
Phone: +49-731-500-45707  
Fax: +49-731-500-45525  
E-Mail: verena.gaidzik@uniklinik-ulm.de  
Current Position: Clinical Fellow/Scientist, Department of Internal Medicine III, Ulm University

### 2. University Education

26.05.2005 Medical Licensing Examination  
1998-2005 Medical School, Ulm University

### 3. Academic Degrees

10.06.2005 Doctoral Thesis (*Dr. med.*), Medicine, Ulm, University, Advisor: Prof. Peter Gierschik  
03.07.2012 Board Certification in Internal Medicine

### 4. Professional Experience

since 06/2005 Fellowship in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases; Department of Internal Medicine III, Ulm University (Director: Prof. Dr. H. Döhner)

### 5. Honors

2007-2011 Travel awards of EHA  
2006-2010 Travel awards of ASH  
2009 Translational Research Training in Hematology Award (TRTH), American Society of Hematology (ASH) and European Hematology Association (EHA)  
2012 "Gerok" grant of the Medical Faculty

### 6. Publications

1. Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L,\* Döhner K.\* TET2 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis of the AML Study Group (AMLSG). *J Clin Oncol.* 2012;30(12):1350-7. \*Equal contribution.
2. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf I GH, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K. RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis on 945 Patients from the AML Study Group (AMLSG). *J Clin Oncol.* 2011;29(10):1364-72.
3. Bullinger L, Krönke J, Schön C, Radtke I, Urlbauer K, Botzenhardt U, Gaidzik V, Carió A, Senger C, Schlenk RF, Downing JR, Holzmann K, Döhner K, Döhner H. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. *Leukemia.* 2010;24:438-49.
4. Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K, for the German-Austrian AML Study Group

- (AMLSG). Prognostic impact of *WT1* mutations in cytogenetically normal acute myeloid leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG). *Blood*. 2009;113:4505-11.
5. Gaidzik V and Döhner K: Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. **Semin Oncol**. 2008;35:324-325.